Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Margenza

Last reviewed on RxList: 1/13/2021
Margenza Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Margenza?

Margenza (margetuximab-cmkb) is a HER2/neureceptor antagonist indicated, in combination with chemotherapy, to treat adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

What Are Side Effects of Margenza?

Side effects of Margenza in combination with chemotherapy include:

  • fatigue,
  • weakness,
  • nausea,
  • diarrhea,
  • vomiting,
  • constipation,
  • headache,
  • fever,
  • hair loss,
  • abdominal pain,
  • numbness and tingling in extremities,
  • joint or muscle pain,
  • cough,
  • decreased appetite,
  • shortness of breath,
  • infusion-related reactions,
  • hand-foot syndrome (palmar-plantar erythrodysesthesia), and
  • extremity pain

Dosage for Margenza

Margenza is administered as an intravenous infusion at 15 mg/kg over 120 minutes for the initial dose, then over a minimum of 30 minutes every 3 weeks for all subsequent doses.

Margenza In Children

The safety and effectiveness of Margenza have not been established in pediatric patients.

What Drugs, Substances, or Supplements Interact with Margenza?

Margenza may interact with other medicines such as:

  • anthracyclines

Tell your doctor all medications and supplements you use.

Margenza During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Margenza; it may harm a fetus. The pregnancy status of females of reproductive potential should be verified prior to initiation of Margenza. Women who received Margenza during pregnancy or within 4 months prior to conception should be monitored for too little amniotic fluid (oligohydramnios). Females of reproductive potential are advised to use effective contraception during treatment and for 4 months following the last dose of Margenza. It is unknown if Margenza passes into breast milk or how it would affect a nursing infant. Consult your doctor before breastfeeding.

Additional Information

Our Margenza (margetuximab-cmkb) Injection, for Intravenous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Breast Cancer Awareness: Symptoms, Diagnosis, and Treatment See Slideshow
Margenza Professional Information

SIDE EFFECTS

The following adverse reactions are discussed in greater detail in other sections of the label:

  • Left Ventricular Dysfunction [see WARNINGS AND PRECAUTIONS]
  • Embryo-Fetal Toxicity [see WARNINGS AND PRECAUTIONS]
  • Infusion-Related Reactions [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice.

The safety of MARGENZA was evaluated in HER2-positive breast cancer patients who received two or more prior anti-HER2 regimens in SOPHIA [see Clinical Studies].

Patients were randomized (1:1) to receive either MARGENZA 15 mg/kg every 3 weeks plus chemotherapy or trastuzumab plus chemotherapy. Among patients who received MARGENZA, 40% were exposed for 6 months or longer and 11% were exposed for greater than one year.

Serious adverse reactions occurred in 16% of patients who received MARGENZA. Serious adverse reactions in > 1% of patients included febrile neutropenia (1.5%), neutropenia/neutrophil count decrease (1.5%) and infusion related reactions (1.1%). Fatal adverse reactions occurred in 1.1% of patients who received MARGENZA, including viral pneumonia (0.8%) and aspiration pneumonia (0.4%).

Permanent discontinuation due to an adverse reaction occurred in 3% of patients who received MARGENZA. Adverse reactions which resulted in permanent discontinuation in > 1% of patients who received MARGENZA included left ventricular dysfunction and infusion related reactions.

Dosage interruptions due to an adverse reaction occurred in 11% of patients who received MARGENZA. Adverse reactions which required dosage interruption in > 5% of patients who received MARGENZA included infusion related reactions.

Table 1 summarizes the adverse reactions in SOPHIA.

Table 1 : Adverse Reactions (>10%) in Patients with Metastatic HER2-Positive Breast Cancer Who Received MARGENZA in SOPHIA

Adverse ReactionMARGENZA + Chemotherapy
(n = 264)
Trastuzumab + Chemotherapy
(n = 266)
All Grades (%)Grade 3 or 4 (%)All Grades (%)Grade 3 or 4 (%)
General disorders and administration site conditions
Fatigue/Asthenia577474.5
Pyrexia190.4140.4
Gastrointestinal disorders
Nausea331.1320.4
Diarrhea252.3252.3
Vomiting210.8141.5
Constipation190.8170.8
Abdominal paina171.5211.5
Skin and Subcutaneous tissue
Alopecia180150
Palmar-plantar erythrodysesthesia130153
Nervous System Disorders
Headacheb190160
Peripheral neuropathyc161.1152.3
Respiratory, thoracic and mediastinal disorders
Cough140.4120
Dyspnea131.1112.3
Metabolism and nutrition disorders
Decreased appetite140.4140.4
Musculoskeletal and connective tissue disorders
Arthralgia/Myalgia140.4120.8
Extremity pain110.890
a Includes abdominal pain, abdominal discomfort, lower abdominal pain and upper abdominal pain
b Includes headache and migraine
c Includes peripheral neuropathy, peripheral sensory neuropathy, peripheral motor neuropathy, and neuropathy

Clinically relevant adverse reactions in ≤10% of patients who received MARGENZA in combination with chemotherapy included: dizziness and stomatitis (10%) each, decreased weight, dysgeusia, rash, and insomnia (6%) each, hypertension (5%), and syncope (1.5%).

Table 2 summarizes the laboratory abnormalities in SOPHIA.

Table 2 : Select Laboratory Abnormalities (>20%) That Worsened from Baseline in Patients with Metastatic HER2-Positive Breast Cancer Who Received MARGENZA in SOPHIA

Laboratory AbnormalityMARGENZA + chemotherapy1Trastuzumab + chemotherapy1
All Grades (%)Grade 3 or 4 (%)All Grades (%)Grade 3 or 4 (%)
Hematology
Decreased hemoglobin523.2432.4
Decreased leukocytes405363.2
Decreased neutrophils349289
Increased aPTT323.4344.3
Decreased lymphocytes314.4384.4
Increased INR241.2250.4
Chemistry
Increased creatinine680.4600
Increased ALT322300.8
Increased lipase306243.2
Increased AST232220.8
Increased alkaline phosphatase210230.8
1 The denominator used to calculate the rate varied from 229 to 253 based on the number of patients with a baseline value and at least one post-treatment value.
aPTT: activated partial thromboplastin time; INR: prothrombin international normalized ratio; ALT: alanine aminotransferase; AST: aspartate aminotransferase

Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity with MARGENZA. The detection of antibody formation is highly dependent on assay sensitivity and specificity. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to MARGENZA in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In SOPHIA, samples were obtained from patients on MARGENZA for immunogenicity testing at baseline, every 2 cycles, and at end of study therapy. All patients enrolled in SOPHIA received trastuzumab previously, and treatment-emergent anti-margetuximab antibodies were observed in 4 patients (1.7%). Of these 4 patients, anti-margetuximab antibodies were detected prior to Cycle 7 of MARGENZA dosing in 1 patient, and more than 2 months after the last MARGENZA dose in 3 patients. In the infusion substudy, treatment-emergent anti-margetuximab antibodies were observed in 2 patients (3.8%). Of these 2 patients, anti-margetuximab antibodies were detected prior to Cycle 3 of MARGENZA dosing in 1 patient, and more than 6 months after the last MARGENZA dose in 1 patient. Due to the limited number of patients who developed antimargetuximab antibodies during treatment with MARGENZA, the impact of anti-margetuximab antibodies on the PK, safety and efficacy of MARGENZA is unknown.

Read the entire FDA prescribing information for Margenza (Margetuximab-cmkb Injection, for Intravenous Use)

QUESTION

A lump in the breast is almost always cancer. See Answer
Related Resources for Margenza

© Margenza Patient Information is supplied by Cerner Multum, Inc. and Margenza Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors